OSLO, Norway, May 6, 2020 /PRNewswire/ -- Targovax ASA (OSE:
TRVX), a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors, today
announces that interim phase I clinical data from the phase I/II
trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in
patients with peritoneal disease originating from ovarian or
colorectal cancer, will be presented at the ASCO20 Virtual
Scientific conference, 29-31 May
2020. The trial is a collaboration with Cancer Research
Institute (CRI) and Ludwig Cancer Research (Ludwig, trial sponsor)
and AstraZeneca.
The abstract will be released on 13 May
on https://meetings.asco.org/am/virtual-format.
Abstract
title:
|
Phase I/II
study to evaluate systemic durvalumab + intraperitoneal (IP)
ONCOS-102 in patients with peritoneal disease who have epithelial
ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I
clinical and translational results.
|
Abstract
no.:
|
3017
|
Presenter:
|
Dmitriy Zamarin,
MD, PhD
|
CONTACT:
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-that-abstract-on-interim-phase-i-clinical-data-from-the-phase-i-ii-peritoneal-tri,c3104915